PAS
AMED

Park Avenue Securities’s Amedisys AMED Stock Holding History

Park Avenue Securities’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,439
Closed -$454K – 715
2022
Q4 		$454K Sell
5,439
-458
-8% -$41.3K 0.01% 809
2022
Q3 		$571K Sell
5,897
-129
-2% -$15.4K 0.01% 658
2022
Q2 		$633K Sell
6,026
-224
-4% -$28.6K 0.01% 621
2022
Q1 		$1.08M Buy
6,250
+710
+13% +$106K 0.02% 455
2021
Q4 		$897K Buy
5,540
+1,773
+47% +$285K 0.02% 515
2021
Q3 		$562K Buy
3,767
+218
+6% +$45.3K 0.01% 592
2021
Q2 		$869K Buy
3,549
+1,012
+40% +$266K 0.02% 458
2021
Q1 		$672K Buy
2,537
+795
+46% +$224K 0.02% 490
2020
Q4 		$511K Buy
1,742
+390
+29% +$100K 0.01% 494
2020
Q3 		$320K Buy
+1,352
New +$307K 0.01% 550

Other funds holding AMED

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RP
Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Park Avenue Securities's AMED Position: Q1 2023 in Review

Park Avenue Securities sold out of Amedisys (AMED) in Q1 2023, closing a stake of 5,439 shares — an estimated $454K sold.

Park Avenue Securities first reported a position in AMED in Q3 2020 and held it in 10 quarters. The position peaked at $1.08M in Q1 2022. 281 funds tracked by Wall St. Rank hold AMED as of Q1 2023.

  • Park Avenue Securities reported no remaining Amedisys position as of Q1 2023 after selling out during the quarter.
  • Park Avenue Securities sold 5,439 Amedisys shares in Q1 2023, an estimated $454K.
  • Park Avenue Securities first reported a position in Amedisys in Q3 2020 and held it in 10 quarters.
  • Park Avenue Securities's Amedisys position peaked at $1.08M in Q1 2022.
  • 281 funds tracked by Wall St. Rank held Amedisys as of Q1 2023.

Based on Park Avenue Securities's 13F filing for Q1 2023, filed 18 Apr 2023.